Viscosupplementation Market

Viscosupplementation Market Outlook

The global viscosupplementation market is anticipated to expand at a moderate CAGR of 5.7% during the forecast period. The industry is likely to cross a valuation of USD 3,777.4 million by 2034.

Due to an expanding senior population, the viscosupplementation treatment industry is anticipated to accelerate progressively from 2024 to 2034. As a result, the sales of viscosupplementation are estimated to reach USD 2,167.3 million in 2024.

Rising demand for non-surgical osteoarthritis treatments, the prevalence of lifestyle-related illnesses, and advances in the development of hyaluronic acid-based therapies are all projected to strengthen the market.

Emerging Patterns in the Viscosupplementation Market

• Osteoarthritis is becoming prevalent globally, owing primarily to aging populations and lifestyle choices. This has resulted in an upsurge in demand for viscosupplementation as a non-surgical treatment for osteoarthritis symptoms.
• The viscosupplementation treatment market has experienced some consolidation, with mergers and acquisitions taking place among prominent competitors. This trend is expected to continue as businesses strive to strengthen their market positions and diversify their product offerings.
• Both healthcare professionals and patients are becoming more aware of the potential advantages of viscosupplementation. As a result, more people are choosing this less invasive method over standard therapies such as painkillers or surgery.

Attributes	Details
Market Value for 2024	USD 2,167.3 million
Market Value for 2034	USD 3,777.4 million
Market CAGR from 2024 to 2034	5.7%

The Impact of Aging Populations on Osteoarthritis Treatment Trends

The industry is undergoing a substantial change due to an aging population. As people age, their risk of developing osteoarthritis rises, increasing the demand for effective treatments.

Viscosupplementation emerges as a feasible option, providing a non-surgical way to control joint discomfort and enhance mobility in elderly individuals. The growing aging demographic serves as a primary driver for the market expansion of viscosupplementation, with healthcare professionals increasingly focused on addressing the special needs of this age segment.

The Evolution of Viscosupplementation Through Technological Breakthroughs

Continuous technological improvements substantially impact the evolution of viscosupplementation, improving its efficacy and patient comfort. Innovations in viscosupplement formulation, delivery techniques, and overall performance lead to increased viscosity, durability, and effectiveness throughout time.

The advances in technology make the treatment more appealing to patients and attract healthcare practitioners who want cutting-edge solutions for their patients. The viscosupplementation market thrives on technological advancement, with constant research and development efforts boosting innovation and ensuring that viscosupplementation remains a cutting-edge choice in the treatment of osteoarthritis.

The Rise of Viscosupplementation in Joint Care

Viscosupplementation's attraction is heightened by its correlation with fewer side effects and a shorter recovery time than surgical procedures. Patients are generally drawn to treatments that provide excellent relief, pose fewer hazards, and require shorter recovery times.

This choice improves the market by establishing viscosupplementation as an appealing option for people looking for a balance of efficacy and minimal disruption in their daily lives. The emphasis on patient safety and convenience helps the viscosupplementation market expansion, as viscosupplementation becomes a popular alternative for individuals preferring a faster and smoother recovery experience.

Market Growth Hurdle of Regulatory Restraints in Viscosupplementation

Regulations impose significant obstacles on the viscosupplementation market. Health authorities' stringent regulatory procedures for approving viscosupplements can stifle market expansion of viscosupplementation.

Complex and long approval processes deter firms from releasing new items or limit their capacity to respond rapidly to viscosupplementation demands. Regulatory uncertainty and developing standards are expected to present vendor challenges, resulting in product launch delays and increased compliance costs.

Tracing the Evolution of the Viscosupplementation Market Between 2019 and 2023 and Future Prospects Between 2024 and 2034

Short-term Analysis (From 2019 to 2023):

The viscosupplementation equipment market grew steadily, driven by increasing awareness, aging demographics, and rising orthopedic diseases. Product formulation innovations and expanding uses helped to sustain the market's favorable trend.

Attributes	Details
Market CAGR from 2019 to 2023	4.4%

Mid-term Analysis (From 2024 to 2029):

Advancements in medical technology, combined with an increasing emphasis on less invasive therapies, are projected to propel the viscosupplementation industry. Increased collaboration among viscosupplementation vendors and healthcare providers is anticipated to be critical to viscosupplementation market growth.

Long-term Analysis (From 2029 to 2034):

Due to ongoing research and development, the viscosupplementation equipment market is expected to increase steadily by 2034. Evolving reimbursement regulations and a better awareness of the benefits of viscosupplements are likely to help the market grow in the long run.

Category-wise Outlook

The segmented market analysis of viscosupplementation is included in the following subsection. Based on comprehensive studies, the three injection viscosupplementation sector is leading the product category, and the ambulatory surgical center segment is commanding the end user category.

Three Injection Viscosupplementation to Acquire a 48.4% Share in 2024

The three-injection viscosupplementation category is estimated to dominate the market in 2024, accounting for 48.4%. Given the following, it makes sense:

Leading Segment	Three Injection Viscosupplementation
Segment Share	48.4%

• The demand for three-injection viscosupplementation reflects a growing need for effective but manageable osteoarthritis treatment choices.
• The dominant sales position of the three-injection viscosupplementation demonstrates market acceptance as a clinically sound, patient-friendly therapy option.
• The three-injection viscosupplementation is a popular alternative due to its mix of therapy effectiveness and patient convenience, which has fueled its market leadership.

Ambulatory Surgical Centers Segment to Garner a 31.9% Share in 2024

The ambulatory surgical centers sector is expected to rule the viscosupplementation treatment market in 2024 with a 31.9% market share. Several aspects of the choice include:

Leading Segment	Ambulatory Surgical Centers
Segment Share	31.9%

• The expanding trend of outpatient orthopedic care is consistent with the ambulatory surgical centers concept, making it an attractive option for viscosupplementation sales.
• Compared to traditional hospital settings, ambulatory surgical centers are frequently a less expensive option for viscosupplementation operations.
• Ambulatory surgical centers provide convenient and specialized facilities for outpatient joint operations, which promotes the demand for viscosupplementation.

Country-wise Analysis

The following tables show the viscosupplementation market, focusing on the largest economies in North America, Europe, and Asia Pacific. A thorough analysis reveals that China has significant prospects due to its resilient viscosupplementation producers.

Viscosupplementation Industry in China

With great potential, the China viscosupplementation market is expected to continue to thrive at a steady CAGR of 9.0% through 2034. This expansion is supported by:

Country	China
CAGR	9.0%

• Enhanced opportunities for viscosupplementation treatments are made possible by China's rapidly growing healthcare infrastructure, consistent with the nation's goal of improving healthcare services.
• By assuring product quality and safety, the Chinese government's emphasis on encouraging innovation in healthcare and creating a favorable regulatory environment promotes the market growth of viscosupplementation.
• The technological developments and affordability of viscosupplements in the Chinese market are attributed to strategic partnerships between multinational pharmaceutical corporations and local manufacturers.

Viscosupplementation Industry in Japan

The Japan viscosupplementation treatment market is expected to evolve at a CAGR of 8.5% through 2034. The following is an explanation of this:

Country	Japan
CAGR	8.5%

• The adoption of viscosupplementation into holistic pain management strategies is gaining acceptance in Japan, encouraging collaboration between orthopedic physicians and pain management experts.
• Japan's viscosupplementation industry is experiencing a spike in demand, surged by the aging population and the cultural importance of maintaining joint health for a more active life.
• Traditional medical practices, such as Kampo medicine, combine with contemporary treatments, impacting patient preferences and the entire market landscape for viscosupplementation in Japan.

Viscosupplementation Industry in Brazil

Brazil viscosupplementation market is expected to flourish at a 6.2% CAGR through 2034. This expansion is maintained by:

Country	Brazil
CAGR	6.2%

• The growing senior population and more awareness about osteoarthritis management are propelling growth in Brazil's viscosupplementation industry.
• Government actions to improve healthcare infrastructure and cost significantly impact the adoption of viscosupplements in Brazil.
• Cultural developments toward a more active lifestyle contribute to the demand for viscosupplementation in Brazil as people seek effective joint health treatments.

Viscosupplementation Industry in Germany

The Germany viscosupplementation treatment market is anticipated to evolve at a constant 4.0% CAGR through 2034. This is clarified by:

Country	Germany
CAGR	4.0%

• The robust healthcare infrastructure and well-established reimbursement processes in Germany benefit the pricing and accessibility of viscosupplementation therapy.
• Cultural considerations, such as a strong emphasis on health and fitness, help to escalate the viscosupplementation market in Germany.
• German healthcare practitioners' preference for individualized medicine generates demand for customized viscosupplementation approaches that address individual patient demands.

Viscosupplementation Industry in the United States

The United States viscosupplementation market is expected to foster a 3.9% CAGR through 2034. An outline of this is given below:

Country	United States
CAGR	3.9%

• The United States viscosupplementation industry is pushed by an aging population, highlighting the need for joint care solutions.
• Insurance coverage and reimbursement policies influence the availability and acceptance of viscosupplements in the United States viscosupplementation equipment market.
• Increased awareness of lifestyle-related joint disorders has stimulated viscosupplementation market expansion, with patients actively pursuing preventive measures.

Competitive Analysis

Prominent viscosupplementation vendors are vital in determining the competitive environment, and each one advances the expansion and improvement of the sector. Sanofi S.A. is a notable viscosupplementation provider, offering its knowledge and inventiveness.

Zimmer While Bioventus LLC and Anika Therapeutics Inc. offer distinctive advantages and contributions to the viscosupplementation market, Biomet Holdings Inc. is another important participant recognized for its noteworthy achievements. The pharmaceutical experience of Fidia Farmaceutici S.p.A. and Ferring B.V. adds to the market's varied portfolio.

Notable viscosupplementation producers promoting improvements in medical science include Seikagaku Corporation and Chugai Pharmaceutical Co., Ltd. OrthogenRx Inc., which contributes unique advantages to the competitive environment. At the same time, Mylan N.V. expands the market through its presence.

The major viscosupplementation manufacturers collectively influence the market dynamics, propelling innovations, dependability, and creativity in the industry. Continuous improvement is expected as they negotiate the market's potential and difficulties, guaranteeing the evolution of viscosupplementation for better patient care.

Noteworthy Advancements

Company	Details
Juniper Biologics	A license agreement was made in April 2022 between Juniper Biologics and Kolon Life Sciences to develop and commercialize TissueGene-C low dose (TG-C LD). This experimental non-surgical treatment is injected once into the joint to treat osteoarthritis in the knee.
OrthogenRx, Inc.	OrthogenRx, Inc., a pioneer in viscosupplementation therapies for knee osteoarthritis, was purchased by the medical technology company Avanos Medical in December 2021. Avanos uses the FDA-approved GenVisc850 and TriVisc.
Ono Pharmaceutical Co., Ltd.	Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation introduced JOYCLU 30mg intra-articular injection in May 2021. Seikagaku was granted manufacturing and marketing approval in Japan in March 2021 for this joint function enhancement agent.
Sanofi S.A.	Sanofi S.A.'s 'Synvisc-one' viscosupplement combines two cross-linked polymers with hyaluronic acid formulations. Due to its synthetic makeup, it can operate as a gel and a fluid. The high molecular weight is said to increase the therapeutic efficacy over the long run.
Anika Therapeutics, Inc.	At the International Cartilage Regeneration and Joint Preservation Society (ICRS), Anika Therapeutics, Inc. revealed Hyalofast, a hyaluronic acid-based scaffold for cartilage regeneration.
DUROLANE	FDA-approved DUROLANE, a Bioventus single-injection H.A. medication, is intended to relieve knee osteoarthritis pain.

Prominent Viscosupplementation Manufacturers

• Sanofi S.A.
• Zimmer Biomet Holdings Inc.
• Bioventus LLC
• Anika Therapeutics Inc.
• Fidia Farmaceutici S.p.A.
• Ferring B.V.
• Seikagaku Corporation
• Chugai Pharmaceutical Co., Ltd.
• OrthogenRx Inc.
• Mylan N.V.

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
• 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
  • 5.1. Single Injection Viscosupplementation
  • 5.2. Three Injection Viscosupplementation
  • 5.3. Five Injection Viscosupplementation
• 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
  • 6.1. Knee Osteoarthritis
  • 6.2. Hip Osteoarthritis
  • 6.3. Shoulder Osteoarthritis
  • 6.4. Others
• 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
  • 7.1. Hospitals
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Orthopedic Clinics
  • 7.4. Retail Pharmacies
  • 7.5. Online Sales
• 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
  • 8.1. North America
  • 8.2. Latin America
  • 8.3. Western Europe
  • 8.4. Eastern Europe
  • 8.5. South Asia and Pacific
  • 8.6. East Asia
  • 8.7. Middle East and Africa
• 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 16. Key Countries Market Analysis
• 17. Market Structure Analysis
• 18. Competition Analysis
  • 18.1. Sanofi S.A.
  • 18.2. Zimmer Biomet Holdings Inc.
  • 18.3. Bioventus LLC
  • 18.4. Anika Therapeutics Inc.
  • 18.5. Fidia Farmaceutici S.p.A.
  • 18.6. Ferring B.V.
  • 18.7. Seikagaku Corporation
  • 18.8. Chugai Pharmaceutical Co., Ltd.
  • 18.9. OrthogenRx Inc.
  • 18.10. Mylan N.V.
• 19. Assumptions & Acronyms Used
• 20. Research Methodology